Abstract
Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.
Keywords: Inhaled corticosteroids, cystic fibrosis, adverse effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Inhaled Corticosteroids In Treatment of Cystic Fibrosis
Volume: 11 Issue: 3
Author(s): Ela Erdem and Refika Ersu
Affiliation:
Keywords: Inhaled corticosteroids, cystic fibrosis, adverse effects
Abstract: Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.
Export Options
About this article
Cite this article as:
Erdem Ela and Ersu Refika, Inhaled Corticosteroids In Treatment of Cystic Fibrosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (3) . https://dx.doi.org/10.2174/1871523011202030206
DOI https://dx.doi.org/10.2174/1871523011202030206 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development, Validation and Results of Quantitative Stability Testing for Gastrografin<sup>®</sup>
Current Pharmaceutical Analysis Nanocarriers for Effective Topical Delivery of Anti-Infectives
Current Nanoscience The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells
Current Pharmaceutical Design The Role of Neurogenic Bioamines in Nerve Fibers of Uterus during the Postpartum Involution in Experimental Animal Models
Current Pharmaceutical Design Review of the Relationship between Renal and Retinal Microangiopathy in Diabetes Mellitus Patients
Current Diabetes Reviews Cytomegalovirus Prophylaxis in Solid Organ Transplantation
Current Medicinal Chemistry Familial Mediterranean Fever
Current Rheumatology Reviews Alpha 1 Anti-Trypsin: One Protein, Many Functions
Current Molecular Medicine Synthesis of Diflunisal Thiazolidinones as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Irritable Bowel Syndrome: A Clinical Review
Current Rheumatology Reviews Synthesis and Antitumor Activity of Novel N-Benzoyl-N'-substituted Pyrimidinyl (Thio)semicarbazide Derivatives
Letters in Drug Design & Discovery Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Developing Antiangiogenic Peptide Drugs for Angiogenesis-Related Diseases
Current Pharmaceutical Design The mir-221/222 Cluster is a Key Player in Vascular Biology via the Fine-Tuning of Endothelial Cell Physiology
Current Vascular Pharmacology Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia
Current Molecular Medicine Current Advances in Anti-Influenza Therapy
Current Medicinal Chemistry Current Research on Opioid Receptor Function
Current Drug Targets Structure and Function of Complement Activating Enzyme Complexes C1 and MBL-MASPs
Current Protein & Peptide Science Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Bradykinin B2 receptors play a neuroprotective role in Hypoxia/reoxygenation injury related to pyroptosis pathway
Current Neurovascular Research